Tags

Type your tag names separated by a space and hit enter

Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
Am J Psychiatry 2003; 160(6):1117-24AJ

Abstract

OBJECTIVE

The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested.

METHOD

Public-sector psychiatric patients with long histories of antipsychotic treatment and presumably long-standing tardive dyskinesia were randomly assigned to receive branched-chain amino acids or placebo. Treatment frequency was three times a day, 7 days a week for 3 weeks. The efficacy measure was a frequency count of videotaped tardive dyskinesia movements.

RESULTS

A robust and highly significant difference was observed between patients who received high-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.) (N=18) and those who received placebo (N=18) in the percent change in tardive dyskinesia symptoms from baseline to the end of the 3-week trial. Significant and marked differences were seen between the two groups at the >/=30% and >/=60% levels of decrease in tardive dyskinesia symptoms. No clinically significant differences were seen between the pre- and posttrial results of physical examinations and laboratory screening tests. Minimal gastrointestinal symptoms occurred during the trial. The reduction in tardive dyskinesia symptoms in the amino acids group was not related to changes in antipsychotic and glucose plasma levels. A mechanism of response related to decreased amine neurotransmitter synthesis was suggested by the significant positive correlations observed between decreases in tardive dyskinesia symptoms and decreases in aromatic amino acid plasma concentrations over the course of the trial.

CONCLUSIONS

Branched-chain amino acids constitute a novel, safe treatment for tardive dyskinesia, with a strong potential for providing significant improvement in the diseased physiognomy of the afflicted person.

Authors+Show Affiliations

Division of Movement Disorders and Molecular Psychiatry, Nathan S. Kine Institute for Psychiatric Research, Orangeburg, NY 10962, USA. marich@nki.rfmh.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12777270

Citation

Richardson, Mary Ann, et al. "Efficacy of the Branched-chain Amino Acids in the Treatment of Tardive Dyskinesia in Men." The American Journal of Psychiatry, vol. 160, no. 6, 2003, pp. 1117-24.
Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160(6):1117-24.
Richardson, M. A., Bevans, M. L., Read, L. L., Chao, H. M., Clelland, J. D., Suckow, R. F., ... Citrome, L. (2003). Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. The American Journal of Psychiatry, 160(6), pp. 1117-24.
Richardson MA, et al. Efficacy of the Branched-chain Amino Acids in the Treatment of Tardive Dyskinesia in Men. Am J Psychiatry. 2003;160(6):1117-24. PubMed PMID: 12777270.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. AU - Richardson,Mary Ann, AU - Bevans,Margaret L, AU - Read,Laura L, AU - Chao,Helen M, AU - Clelland,James D, AU - Suckow,Raymond F, AU - Maher,Timothy J, AU - Citrome,Leslie, PY - 2003/6/5/pubmed PY - 2003/7/24/medline PY - 2003/6/5/entrez SP - 1117 EP - 24 JF - The American journal of psychiatry JO - Am J Psychiatry VL - 160 IS - 6 N2 - OBJECTIVE: The efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men with psychiatric disorders was tested. METHOD: Public-sector psychiatric patients with long histories of antipsychotic treatment and presumably long-standing tardive dyskinesia were randomly assigned to receive branched-chain amino acids or placebo. Treatment frequency was three times a day, 7 days a week for 3 weeks. The efficacy measure was a frequency count of videotaped tardive dyskinesia movements. RESULTS: A robust and highly significant difference was observed between patients who received high-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.) (N=18) and those who received placebo (N=18) in the percent change in tardive dyskinesia symptoms from baseline to the end of the 3-week trial. Significant and marked differences were seen between the two groups at the >/=30% and >/=60% levels of decrease in tardive dyskinesia symptoms. No clinically significant differences were seen between the pre- and posttrial results of physical examinations and laboratory screening tests. Minimal gastrointestinal symptoms occurred during the trial. The reduction in tardive dyskinesia symptoms in the amino acids group was not related to changes in antipsychotic and glucose plasma levels. A mechanism of response related to decreased amine neurotransmitter synthesis was suggested by the significant positive correlations observed between decreases in tardive dyskinesia symptoms and decreases in aromatic amino acid plasma concentrations over the course of the trial. CONCLUSIONS: Branched-chain amino acids constitute a novel, safe treatment for tardive dyskinesia, with a strong potential for providing significant improvement in the diseased physiognomy of the afflicted person. SN - 0002-953X UR - https://www.unboundmedicine.com/medline/citation/12777270/full_citation L2 - https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.160.6.1117?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -